Investor Centre
Our pipeline and lead compound SFX-01 is derived from our proprietary Sulforadex® technology.
0.75 GBX
Volume:
14,825
Market Capitalisation (m)
£3.21
Corporate Presentation
Acquisition, Fundraising and Change of Name
19 - March - 2024Evgen announces the acquisition of Chronos Therapeutics, placing and subscription offer and company name change.
Investor Meet Presentation – Proposed Acquisition of Chronos Therapeutics Ltd, Placing and Accompanying Retail Offer
21 - March - 2024CEO Dr Huw Jones, CBO Dr Helen Kuhlman and new CFO Toni Haenninen discuss Evgen's proposed acquisition of Chronos Therapeutics Ltd.
| Company | Analyst |
|---|---|
| Cavendish | Chris Donnellan |
Major Shareholder
| Current Shareholder | Number of shares | Percentage holding |
|---|---|---|
| J. R. Kight | 33,100,000 | 7.75% |
| Rathbones Investment Management Ltd | 25,789,246 | 6.03% |
| Octopus Investments | 21,875,000 | 5.12% |
| Vulpes Investment Management Pte Ltd | 20,554,191 | 4.81% |
| First Equity Limited | 20,000,000 | 4.68% |
| Seneca Partners Limited | 16,301,456 | 3.81% |
The number of ordinary shares in issue is 427,346,895 all of which are in public hands. The Company does not hold any shares in Treasury.
